Immunicon Corp

Immunicon — Investor Presentation (May 2005)

32 slides from Immunicon's investor presentation, May 4, 2005

  1. Slide 1: Cellular Information for Better Healthcare

    Slide 1: Cellular Information for Better Healthcare

    © IMMUNICON Cellular Information for Better Healthcare Management Presentation May 2005

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management's current views and opinions as to the status of the Company's products, clinical trials, regulatory approval process, product development, research programs and other future events and operat

  3. Slide 3: Section 1: Company Overview

    Slide 3: Section 1: Company Overview

    SECTION 1 Company Overview

  4. Slide 4: Circulating Tumor Cells (CTCs) in Cancer Diagnostics

    Slide 4: Circulating Tumor Cells (CTCs) in Cancer Diagnostics

    Circulating Tumor Cells (CTCs) in Cancer Diagnostics ABC World News Tonight 8/18/04 © IMMUNICON

  5. Slide 5: Company Overview

    Slide 5: Company Overview

    Company Overview Immunicon develops and is commercializing products for rare cell analysis with an initial focus in cancer: ¢ All FDA clearances for initial products received @ IVD commercialization in progress Strategic alliance with Johnson & Johnson in cancer @ Large market opportunities: Cancer

  6. Slide 6: The Problem

    Slide 6: The Problem

    The Problem Select and Monitor Therapy in Metastatic Disease Diagnosis, Risk Assessment Staging and and Early Selection of Detection Primary Therapy Monitor Effectiveness of Post-Surgical Therapy and Recurrence © IMMUNICON

  7. Slide 7: Section: Technology and Products

    Slide 7: Section: Technology and Products

    SECTION 2 Technology and Products

  8. Slide 8: "Real-Time Biopsy" Using a Blood Sample

    Slide 8: "Real-Time Biopsy" Using a Blood Sample

    “Real-Time Biopsy” Using a Blood Sample Circulating Tumor Cells (CTCs) and Associated Markers: Assess Prognosis Count tam Direct Therapy Monitor Disease Phenotype Diagnose & Genotype =) Specify Therapy 4X ey Determine Fisk Assessment for “~ Presence S) Cancer Most tumors are of epithelial cell origi

  9. Slide 9: CellTracks Technology

    Slide 9: CellTracks Technology

    CellTracks® Technology v7 a “cellsave Ra Nucl \. Acid/Protein 4Feelitracks “Analyses salpappten Cell Seai rch [ | — #cellspotter celitracks : © IMMUNICON

  10. Slide 10: A New Paradigm for Cancer Disease Management

    Slide 10: A New Paradigm for Cancer Disease Management

    A New Paradigm for Cancer Disease Management Current standard: Potential future standard: Radiologist measures changes in Number and/or makeup of CTCs better lesions on a CT scan to assess reflects efficacy of treatment tumor burden increase/decrease Subjective and semi-quantitative Objective and qu

  11. Slide 11: NEJM 8/19/04: CTCs Predict Survival

    Slide 11: NEJM 8/19/04: CTCs Predict Survival

    NEJM 8/19/04: CTCs Predict Survival %Probability of Survival Before initiation of therapy >18 months >5 CTCs (N=87) N=177 Logrank < 0.0001 7 T TI ot 10 15 20 25 30°35 40 45 50 55 60 65 70 75 80 Time from start of therapy (Weeks) © IMMUNICON 1 05

  12. Slide 12: NEJM 8/19/04: CTCs Predict Survival at 1st Follow-Up

    Slide 12: NEJM 8/19/04: CTCs Predict Survival at 1st Follow-Up

    NEJM 8/19/04: CTCs Predict Survival at 1‘ Follow-Up ~4 weeks after initiation of therapy 100% zo <5 CTCs S s0%] (N=114) Z m4 Seow >18 Months 60% S$ 0% 1 3 | H >5CTCs & 30% H aa (N=49) soe] i N=163 0%-4 H Logrank < 0.0001 Pa a 10-15 20 25 30 35 40 45 50 55 60 65 70 75 80 Time from 1st Follow-Up (Week

  13. Slide 13: NEJM 8/19/04: Proven Clinical Utility

    Slide 13: NEJM 8/19/04: Proven Clinical Utility

    NEJM 8/19/04: Proven Clinical Utility Current measures to determine if therapy is effective are inadequate #CTCs are an independent prognostic indicator of favorable & unfavorable outcomes (PFS and OS) When elevated, CTCs predict short PFS and OS and may indicate patient is on a futile therapy «Furt

  14. Slide 14: New FDA Classification

    Slide 14: New FDA Classification

    3 New FDA Classification Classification received through “de novo” process: Simplifies/shortens regulatory timelines (510(k) process) Written into Code of Federal Regulations (866.6020) @ FDA “special controls” guidance document issued @ Creates a significant barrier to entry ° FDA cleared labeling:

  15. Slide 15: "Real-Time Biopsy" from a Blood Sample

    Slide 15: "Real-Time Biopsy" from a Blood Sample

    “Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies Taxol Herceptin 225 2 oe oe ee @ 175 E 150 495, BE ogee DO ver = 100 2 75 Di tera + pera - 5 80 5 2 0 | al 012 3 45 6 7 8 9 1011 12 13 14 15 16 17 18 19 20 Time (weeks) > IntJOncol 21: 1111-1118, 2002 " © IMMUNICON

  16. Slide 16: Summary of additional key clinical/scientific findings

    Slide 16: Summary of additional key clinical/scientific findings

    Summary of additional key clinical/scientific findings Breast Cancer “Bone only” disease data encouraging (2005 ASCO) ~ CTCs predict outcome during therapy (2005 ASCO) ~ CTCs a stronger predictor of outcome than imaging Colorectal Cancer ~ Planned interim analysis encouraging ~400 patient labeling s

  17. Slide 17: Completed Modular System

    Slide 17: Completed Modular System

    6 Completed Modular System Low incremental cost to add new applications Sample Sample Sample Sample Collection andy penaration ff} Presentation Analysis Preservation Processed Samples for Off-Line Analyses © IMMUNICON

  18. Slide 18: Many Product Opportunities

    Slide 18: Many Product Opportunities

    w Many Product Opportunities ¢ Potential follow-on CTC applications — Other carcinomas — colorectal, prostate, other... — Other settings — diagnosis, recurrence, risk assessment, — Nucleic acid and protein markers ¢ Endothelial cells — Cancer — angiogenesis — Cardiovascular, autoimmune, + Infectious

  19. Slide 19: Circulating Endothelial Cells (CECs)

    Slide 19: Circulating Endothelial Cells (CECs)

    Circulating Endothelial Cells (CECs) CECs are implicated in cancer, cardiovascular disease, and many other diseases and conditions CECs detected by Immunicon system @ IMMUNICON

  20. Slide 20: Section: Commercialization

    Slide 20: Section: Commercialization

    SECTION 3 Commercialization

  21. Slide 21: Significant Market Opportunity

    Slide 21: Significant Market Opportunity

    Significant Market Opportunity Overall U.S. Market Cancer is the second leading killer — Prevalence: 8.9 million survivors — Incidence: 1.3 million new diagnoses p.a. — Mortality: 500,000 deaths p.a #~86% of all cancers are carcinomas (solid tumors) —CellSearch™ System is ”pan-carcinoma” Cancer Fact

  22. Slide 22: Significant Market Opportunity

    Slide 22: Significant Market Opportunity

    Significant Market Opportunity Cancer Metastatic Pool Breast 78,809 Colorectal 71,136 Prostate 60,449 Other Carcinomas* 304,462 Total 514,856 * Includes melanoma Cancer Facts and Figures 2004, American Cancer Society © IMMUNICON

  23. Slide 23: Strategic Alliance in Cancer with Johnson & Johnson

    Slide 23: Strategic Alliance in Cancer with Johnson & Johnson

    2 Strategic Alliance in Cancer with Johnson & Johnson Key elements: @ Immunicon develops and manufactures # J8J finishes, sells and services # Revenue shared (~30% to IMMC on reagents) @ Access to J&J technology, expertise and distribution # Large equity investment by J8J Development Corp. © IMMUNIC

  24. Slide 24: Selling the Benefits — Product Positioning

    Slide 24: Selling the Benefits — Product Positioning

    2 Selling the Benefits — Product Positioning Blood test ¢ Predictive = real impact in oncology ¢ “Real-time biopsy” = real-time medicine @ Minimally invasive ¢ Convenient and cost-effective Fully integrated system Automation and standardization © IMMUNICON

  25. Slide 25: Sales and Marketing Strategy

    Slide 25: Sales and Marketing Strategy

    Sales and Marketing Strategy Ver ibpex< Surgeons Oncologists “ © IMMUNICON

  26. Slide 26: Section: Financial Overview and Milestones

    Slide 26: Section: Financial Overview and Milestones

    SECTION 4 Financial Overview and Milestones

  27. Slide 27: Attractive Business Model

    Slide 27: Attractive Business Model

    Attractive Business Model Everybody wins. ¢ List price for instrument system = $120,000 ¢ List price to lab for CTC test = $175.00 @ Fast payback for the hospital/reference lab @ High revenue/margins for J&J and Immunicon + Cost effective for the patient/healthcare system Key Drivers for Reimburseme

  28. Slide 28: Financial Summary (quarter ended 3/31/05)

    Slide 28: Financial Summary (quarter ended 3/31/05)

    a Financial Summary (quarter ended 3/31/05) #24 complete systems shipped cumulatively #26 CellTracks AutoPrep Systems and 25 CellSpotter Analyzers Reference labs, hospitals, CRO, major Pharma # Quest (USA) and SRL Japan) are reference labs #Reference labs are multi-placement opportunities @ Systems

  29. Slide 29: Milestones Achieved

    Slide 29: Milestones Achieved

    Milestones Achieved @ Publication in New England Journal of Medicine Q3/04 @ U.S. in vitro diagnostic (IVD) launch Q3/04 ¢ Announced deal with Quest Diagnostics Q3/04 # Shipped units to Europe and Japan (RUO) Q28&Q3/04 ¢ Positive data in “bone only” breast cancer Q4/04 @ Positive interim data in col

  30. Slide 30: Near-term Milestones

    Slide 30: Near-term Milestones

    Near-term Milestones ¢ Several oral/poster presentations at ASCO May 05 @ Launch CellTracks Analyzer II Q2/05 Circulating Endothelial Cells (CECs) — Clinical research studies In progress ~ RUO commercialization In progress @ 510(k) for new data in breast cancer H2/05 © IMMUNICON

  31. Slide 31: Investment Highlights

    Slide 31: Investment Highlights

    Investment Highlights @ Address unmet medical needs in large markets, starting with cancer ° Strategic partnership in cancer with Johnson & Johnson Commercialization process well underway — Compelling clinical data — more on the way! ~ FDA clearances received/passed inspection — ISO 13485:2003 certi

  32. Slide 32: Contact Information

    Slide 32: Contact Information

    Contact Information @ IMMUNICON iver’ to. www.immunic sylvania 19006

Source: SEC EDGAR · 8-K filed May 4, 2005

More decks from Immunicon Corp